Core Viewpoint - At the Annual General Meeting of Octopus Titan VCT plc, over 20 percent of votes were cast against the Board's recommendations for certain resolutions, indicating shareholder dissatisfaction with the company's performance [1] Group 1: Voting Results and Shareholder Feedback - More than 20 percent of votes were against the Board's recommendations for Resolutions 2, 3, and 4, which pertained to the Directors' Remuneration report and the re-election of two directors [1] - The Board attempted to contact shareholders who voted against to understand their reasons, which were primarily linked to Titan's poor investment performance [3] Group 2: Governance and Future Actions - The Board aims to consider shareholder views to enhance governance standards and long-term shareholder value [4] - A Strategic Review was announced on 12 September 2025, with details provided in a Shareholder Circular, which is expected to address shareholder concerns regarding performance [3] - A final update on the voting results and shareholder feedback will be included in the Company's Annual Report for the year ending 31 December 2025 [5]

Core Viewpoint - The upcoming vote for Lifeway Foods' board nominees is critical for restoring accountability and unlocking shareholder value, with a strong emphasis on the need for independent oversight and leadership [2][4]. Group 1: Governance Issues - Lifeway Foods has faced significant governance challenges, with shareholders alleging that the current board has prioritized self-preservation over fiduciary duties, leading to missed opportunities for value realization [3][6]. - The board's response to unsolicited acquisition offers from Danone, including litigation and excessive compensation for the CEO, has been criticized as detrimental to shareholder interests [6][11]. - The newly appointed directors lack relevant experience and independence, raising concerns about the effectiveness of governance reforms [9]. Group 2: Compensation Practices - Lifeway's executive compensation practices are deemed excessive and misaligned with shareholder interests, with recent packages totaling over $8 million for the CEO alone [11]. - The board has been accused of failing to supervise management effectively, particularly during Danone's due diligence process, and of approving unjustified compensation packages [11]. Group 3: Strategic Recommendations - A credible and immediate strategic review and transparent sale process are proposed as the fastest path to unlocking shareholder value, necessitating the formation of an independent Strategic Review & Performance Committee [5][6]. - Shareholders are urged to vote for the dissident nominees and support Proposal 6 to initiate these changes and enforce stricter governance practices [4][12].

Financial Strategy - Delivery Hero is evaluating options to improve its finances and operations [1] - The company is considering changes to its capital structure [1] Shareholder Pressure - Major shareholders are pressuring Delivery Hero to conduct a strategic review [1]

Financial Data and Key Metrics Changes - Consolidated revenues increased by 4.6% year over year, reaching a record of $1.065 billion, with organic growth of 3.4% [8][18] - Non-GAAP earnings per share (EPS) grew by 11% to $1.15, marking the eighth consecutive quarter of beating consensus earnings expectations [5][18] - Free cash flow for Q4 was strong at $150 million, with a total fiscal year repurchase of nearly $300 million, representing about two-thirds of free cash flow [5][19] Business Line Data and Key Metrics Changes - CooperVision reported revenue of $710 million, up 4.9% year over year, with organic growth of 3.2%, driven by improved availability of MyDay lenses [9][10] - CooperSurgical achieved quarterly revenue of $356 million, up 4% or 3.9% organically, with growth in fertility and surgical segments [14][15] Market Data and Key Metrics Changes - The Americas region grew by 5%, while EMEA grew by 3%, slightly below expectations due to market weakness in some countries [10][14] - Asia-Pacific was flat, primarily due to a 28% decline in China, attributed to weakness in low-margin e-commerce channels [10][12] Company Strategy and Development Direction - The company is focused on delivering consistent market share gains for CooperVision, with an emphasis on the MyDay Premium Daily Silicone Hydrogel Lens portfolio [4][6] - A formal strategic review has been initiated to explore opportunities for unlocking long-term shareholder value, including potential separation of business units [8][31][54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about fiscal 2026, expecting strong revenue growth driven by MyDay sales and new private label contracts [39][60] - The company anticipates a conservative approach to guidance, particularly in the fertility segment, while remaining optimistic about long-term growth prospects [15][60] Other Important Information - The board authorized an increase in the share repurchase plan to $2 billion, reinforcing the commitment to returning capital to shareholders [6][19] - The company has successfully remediated material weaknesses related to IT controls from fiscal 2024 [24] Q&A Session Summary Question: Clariti product line performance - Clariti was down a couple of percent this quarter, approaching $400 million in annualized revenue, with ongoing efforts to reposition the product line [25][26] Question: Strategic review process - A strategic review is underway, with updates expected in the next earnings call, focusing on driving long-term shareholder value [30][31] Question: Market growth assumptions - The market is expected to grow at 4%-5% in fiscal 2026, with pricing power remaining stable [33][34] Question: Asia-Pacific market dynamics - The company faced challenges in Asia-Pacific, particularly in low-margin e-commerce channels, but expects less detriment in fiscal 2026 [37][38] Question: Free cash flow outlook - The increase in free cash flow is attributed to consistent performance and reduced capital expenditures, with expectations of over $2.2 billion in free cash flow from fiscal 2026 to 2028 [23][42] Question: Paragard product expectations - Guidance for Paragard includes conservatism due to potential competitive launches, with expectations for flat to low single-digit growth [55] Question: Pipeline and product launches - The company is excited about upcoming product launches, including MyDay and MiSight, which are expected to drive growth [58][59]

Core Points - CooperCompanies has appointed Colleen Jay as the new Chair of the Board, effective January 2, 2026, succeeding Robert Weiss, who will remain on the Board for reelection [1][2] - The company is undergoing a formal strategic review to identify opportunities for enhancing long-term shareholder value [1][4] Leadership Changes - Colleen Jay has been on the Board since 2016 and has a strong background in global operational leadership, having retired from Procter & Gamble in 2017 after 32 years [2] - Robert Weiss has been a significant figure in CooperCompanies' success for nearly five decades, serving in various leadership roles including CEO from 2007 to 2018 [3] Strategic Review - The strategic review aims to improve performance in core markets, expand market share, enhance operational efficiency, and generate strong returns through disciplined capital deployment [4] - The company plans to focus on share repurchases under a $2 billion share repurchase program during this review period [4] Company Overview - CooperCompanies operates in the medical device sector with two main business units: CooperVision, a leader in the contact lens industry, and CooperSurgical, focused on fertility and women's healthcare [5] - The company has a workforce of over 15,000 and sells products in more than 130 countries, positively impacting over 50 million lives annually [5]

Core Thesis - Kenvue Inc. is undergoing a strategic review to optimize its brand portfolio and enhance operating performance, aiming to unlock shareholder value [2][3][4] Company Overview - Kenvue Inc. operates as a consumer health company across multiple regions including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America [2] - As of November 28th, Kenvue's share price was $17.35, with a market capitalization of approximately $30 billion and an enterprise value of around $38 billion [3] Financial Metrics - Kenvue's trailing and forward P/E ratios are 23.13 and 15.77 respectively, with an EV/EBITDA multiple of roughly 11× [1][3] - The company offers a dividend yield of about 4%, providing a solid income component for investors [3] Strategic Initiatives - The strategic review may lead to the sale of underperforming Skin Health & Beauty brands, acquisitions in high-growth OTC health categories, and capital reallocation to higher-margin segments [4] - Analysts estimate that these initiatives could raise Kenvue's margins and overall valuation by 15–25% [4] Investment Case - The combination of a disciplined strategic review, potential divestitures, and a focus on higher-margin segments positions Kenvue to enhance profitability and shareholder returns over time [5] - Kenvue's current valuation and dividend yield, along with strategic initiatives, create an attractive investment case for those seeking operational upside and a clear path to value creation [5]

Core Viewpoint - Delivery Hero SE is under pressure from major shareholders to conduct a strategic review due to increasing consolidation in the food delivery industry and poor stock performance [1][2]. Group 1: Shareholder Pressure - Investors, including Aspex Management, Delivery Hero's second-largest shareholder with over 5% stake, are urging management to consider selling the company or parts of its business [2][4]. - Other investors, such as Broad Peak Investment Advisers and PSquared Asset Management, have expressed frustration over the company's lack of progress in improving its loss-making operations and shareholder value [4]. Group 2: Stock Performance - Delivery Hero's shares have decreased approximately 50% over the past year and nearly 90% from their peak in 2021 [2]. - In recent trading, shares of Delivery Hero rose as much as 15%, reaching a market value of €5.9 billion ($6.9 billion) [3]. Group 3: Strategic Options - Analysts from Barclays noted that there is a growing sentiment among investors for a strategic review and potential asset sales [5]. - Potential buyers for Delivery Hero's assets could include competitors like Meituan, Grab Holdings, or Uber, with the Korean business Baedal Minjok being particularly attractive [5]. Group 4: Governance Implications - Disgruntled investors owning over 5% of Delivery Hero could call for a shareholder meeting and potentially withdraw support for management under German regulations, which could negatively impact executive confidence [6].

Core Viewpoint - Ramsay Health Care Limited has completed a strategic review regarding its majority shareholding in Ramsay Générale de Santé, with plans to execute one of the options considered and provide an update by February 2026 [1][2][3]. Group 1: Strategic Review - Ramsay Health Care Limited announced the completion of its strategic review with the assistance of Goldman Sachs [2]. - The Board and Management of Ramsay Health Care Limited are committed to executing one of the options from the strategic review [3]. - An update on the strategic options will be provided no later than the first half results publication in February 2026 [3]. Group 2: Company Overview - Ramsay Santé is the European leader in private hospitalization and primary care, employing 40,000 staff and 10,000 practitioners [4]. - The group serves 13 million patients annually across 492 facilities in five countries: France, Sweden, Norway, Denmark, and Italy [4]. - Ramsay Santé's mission encompasses a wide range of healthcare services, including medicine, surgery, obstetrics, rehabilitation, mental health, and primary care, focusing on innovation and equitable access to quality care [5].

Core Insights - Waldencast plc reported a 5.6% year-over-year increase in net revenue for Q2 2025, reaching $66.8 million, with an Adjusted EBITDA Margin of 5.0% [2][10] - The company experienced contrasting performances across its brands, with Obagi Medical showing strong growth while Milk Makeup faced challenges in international markets [2][6] - Waldencast has updated its FY 2025 guidance to reflect current trends and investments aimed at long-term growth [1][8] Obagi Medical - Obagi Medical achieved double-digit net revenue growth in Q3 2025, driven by strong e-commerce and international market performance [3][19] - The brand is preparing for the launch of Obagi Saypha®, which will double its addressable market in the U.S. [3][4] - The sale of the Obagi Japan trademark for $82.5 million and credit facility refinancing has strengthened the company's balance sheet [5][8] Milk Makeup - Milk Makeup's net revenue for Q3 2025 was $25.2 million, a decline of 20.1% compared to Q3 2024, despite an 8% increase in U.S. consumption [20][23] - The brand's growth in the U.S. was supported by retail expansion and successful product launches, but international performance was weaker [6][20] - Transformation initiatives are being implemented to revitalize the brand, including team restructuring and increased investment in international markets [7][8] Financial Performance - For H1 2025, Waldencast's net revenue increased by 0.5% year-over-year to $132.3 million, with a net loss of $185.2 million primarily due to impairment charges [13][14] - Adjusted EBITDA for H1 2025 was $7.7 million, representing a margin of 5.8%, down from 13.4% in H1 2024 [15][16] - Q3 2025 net revenue decreased by 3.4% year-over-year to $67.8 million, with Obagi Medical contributing $42.6 million and Milk Makeup $25.2 million [18][23] Strategic Initiatives - Waldencast is conducting a strategic review to maximize shareholder value, having retained Lazard as a financial advisor [8][9] - The company is focused on building a leading dermatological megabrand at the intersection of skincare and medical aesthetics [4][5] - Continued investments in innovation, digital capabilities, and new distribution channels are expected to drive sustainable growth [25][24]

Strategic Review Update - The Trust has been undergoing a strategic review since November 15, 2022, to maximize unitholder value, confirming no further growth in the US under the current platform [1] - The Board will pursue strategies to either sell and exit all current investments and return cash to unitholders or explore the sale or re-utilization of the Trust for another property or platform [1] Financial Performance - The Trust reported a net asset value (NAV) of $5.84 per Trust Unit (CAD $8.18), including disposition costs of assets held for sale [2] - For the three months ended September 30, 2025, net income was approximately $0.13 million, a decrease from $0.27 million in the previous quarter and $0.14 million in the same quarter last year [4] - For the nine months ended September 30, 2025, net income was approximately $0.57 million, compared to a loss of $0.29 million for the same period last year [4][6] Accretive Texas Property Refinancing - The Trust refinanced a $19.1 million fixed-rate mortgage with a new variable-rate mortgage, achieving a 166 basis point interest rate savings, equating to an interest rate of 6.59% [3] - The refinancing is expected to generate an annual AFFO savings of approximately $0.3 million or $0.04 per unit [3] Asset Dispositions - The Trust sold four of six wholly owned assets for gross proceeds of approximately $71.6 million, with net sale proceeds of about $28 million used for debt repayment [5] - The Trust provided seller financing of $4.0 million for its Florida property sale, generating a minimum 9% return that has escalated to 15% [5] - A joint venture property in Maryland was sold for $15.9 million, with the Trust receiving approximately $1.1 million from the sale [5]